Project Grant K01CA296781
Award Date
1/15/25
Completion Date
12/31/29
Dollars Obligated
$192K
Federal Agency
National Cancer Institute
Federal Grant Program
93.398
Assistance Type
Project Grant
Place of Performance
Illinois, USA
Similar Awards
The federal Project Grant award of $233,411 from the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support the "Stories to Prevent (STOP) HPV Cancers" study at Pennsylvania State University's Milton S. Hershey Medical Center. This randomized controlled trial will evaluate a narrative communication intervention delivered through digital and mobile technologies to increase HPV vaccine initiation rates among 9- to 12-year-olds....
The National Cancer Institute (NCI) has awarded a $1,837,497 Cooperative Agreement (CFDA 93.393 - Cancer Cause and Prevention Research) to New York University to implement the KUPEWA project. The goal of the project is to identify optimal implementation strategies for increasing clinician recommendation of HPV vaccination for adolescent girls and young women living with HIV in Malawi. The study will use the Theoretical Domains Framework and WHO's Behavioural and Social Drivers of Vaccination...
This $148,280 Project Grant award from the National Cancer Institute's Cancer Research Manpower program (CFDA 93.398) supports research to investigate the role of ERBB2 signaling in HPV-induced pathologies. The award recipient, Childrens Hospital Medical Center in Cincinnati, Ohio, will utilize 3D organotypic epithelial raft models to spatially resolve ERBB2 expression, activation, and downstream signaling in HPV-positive and HPV-negative samples. The project aims to determine whether ERBB2...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research (CFDA 93.393) program, totaling $1,288,122, aims to identify multi-level factors associated with HPV vaccine uptake in Kenya and Malawi. The key products and services to be delivered include: Primary and secondary data collection on policy, systems, community, and individual-level factors impacting HPV vaccine uptake in Kenya and Malawi. This includes qualitative interviews...
The National Cancer Institute (NCI), under the Cancer Treatment Research Federal Grant Program (CFDA 93.395), awarded a $398,823 Project Grant to Ampedrna Biosciences LLC in Richmond, VA. The grant is for the development of a highly immunogenic mini-circular RNA (mcRNA) therapeutic cancer vaccine targeting human papillomavirus (HPV)-related cancers. The key objectives are to: 1) demonstrate the superior efficacy of a multivalent HPV16 E6/E7 mcRNA vaccine compared to an mRNA vaccine in...
This federal Project Grant award from the National Cancer Institute (CFDA 93.396 Cancer Biology Research) provides $630,506 to The Johns Hopkins University to develop therapeutic cancer vaccines that are effective against diverse variants of human papillomavirus (HPV) 16, which causes over 50% of cervical cancers globally. The primary goal is to employ novel HPV-driven cervicovaginal cancer models to characterize immune evasion mechanisms of different HPV16 E6/E7 variant proteins, evaluate the...
The National Cancer Institute (NCI) awarded a 5-year, $171,989 Project Grant (CFDA 93.398 Cancer Research Manpower) to the University of Florida (UF) to prevent cervical cancer among women with chronic conditions and social vulnerability. The project, titled "Preventing Cervical Cancer Through HPV Self-Collection and Patient Navigation Among Women Living with Chronic Conditions and Social Vulnerability," aims to adapt an evidence-based cervical cancer prevention intervention for this...
The National Cancer Institute (NCI) awarded a $3,942,082 Cooperative Agreement titled "The Mass Partnership for Community-Engaged Cancer Control Equity" to the Harvard T.H. Chan School of Public Health under the Cancer Cause and Prevention Research (CFDA 93.393) federal grant program. This 5-year award aims to advance cancer control equity by strengthening the capacity of community health centers (CHCs) to deliver evidence-based cancer screening and tobacco treatment services, while...
This federal Project Grant award totaling $3,293,053, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), will support a cohort study to evaluate the effectiveness of the HPV vaccine in preventing anogenital disease among immunocompromised populations. The key objectives are to assess vaccine effectiveness for: Preventing incident and recurrent anogenital disease in people living with HIV, those...
The National Cancer Institute (NCI) awarded a $300,374 Project Grant under the Cancer Cause and Prevention Research (CFDA 93.393) program to The University of South Dakota (USD) to develop and test the efficacy of a mobile web app intervention aimed at increasing cervical cancer screening rates among indigenous women in the Yankton Sioux Tribe reservation in South Dakota. The 4-year project will involve a randomized controlled trial to evaluate the feasibility and impact of the...